Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.70
Bid: 28.10
Ask: 30.70
Change: 1.90 (6.60%)
Spread: 2.60 (9.253%)
Open: 28.10
High: 30.70
Low: 28.10
Prev. Close: 28.80
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update

20 Mar 2017 07:00

RNS Number : 8764Z
EKF Diagnostics Holdings PLC
20 March 2017
 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

 

Update

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces the following update for shareholders.

 

The Directors are currently evaluating plans under which they would split the Company into two separate companies based on the business divisions, namely Point of Care and Lab Diagnostics. Whilst both these business divisions are valuable in their own right, the Directors consider that separating the companies out represents a better route for shareholders and one under which they are more likely to achieve a fair reflection of the value of each separate business.

 

However, based on tax advice received by the Company, it is the Directors' understanding that US federal income tax chargeable on any gain associated with the divestiture of the business could be significant. In order to mitigate these potentially adverse tax effects, the distribution needs to qualify as a 'tax-free spinoff'. There are numerous requirements in order to achieve this treatment, including that no acquisition of 50% or more of the shares in either the Company (i.e. the business that remains following the divestiture) or the newly separated company may take place within two years of the separation. Accordingly, the articles of association of the two separate companies would be amended so as to include a prohibition of the sale of 50% or more of the shares in the companies without the consent of their directors.

 

The implementation of the above proposal is envisaged to include a cancellation of the Company's shares from trading on AIM following which it is the Directors current intention to seek a listing of the shares of both companies on a market to be determined.

 

The Directors are sympathetic to individual investors' requirements and therefore in order to provide those shareholders that do not wish to wait for the completion of the restructuring and subsequent potential sale of the two businesses with an exit, the Company is evaluating the possibility of a share buyback offer to shareholders. This share buyback offer would, if completed, be prior to the commencement of the separation and would be at a price of 21.5p per share.

 

There can of course be no guarantee that the above proposals, including any share buyback, will be capable of being completed in the manner currently anticipated. Further announcements will be made at the appropriate time

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Alex Price / Shaun Dobson

Walbrook PR Limited

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDGCGDXRXBBGRC
Date   Source Headline
9th Aug 20187:00 amRNSDiaSpect Tm McKesson US distribution agreement
8th Aug 20184:09 pmRNSHolding(s) in Company
24th Jul 20188:45 amRNSUS distribution agreement for diabetes assay kit
19th Jul 20187:00 amRNSManufacturing partnership with Oragenics, Inc.
4th Jul 20183:15 pmRNSExploring funding options for Renalytix AI
7th Jun 20182:30 pmRNSHolding(s) in Company
1st Jun 201810:00 amRNSUpdate regarding Renalytix AI PLC
31st May 20187:00 amRNSLicence and collaboration agreement signed
8th May 20183:10 pmRNSResult of AGM
18th Apr 201810:36 amRNSPosting of AR and Accounts & Notice of AGM
9th Apr 20188:25 amRNSUS FDA approval for Diaspect Tm
21st Mar 20182:18 pmRNSHolding(s) in Company
14th Mar 20187:00 amRNSFinal Results
21st Feb 20187:00 amRNSNotice of Results
11th Jan 20187:00 amRNSTrading update
29th Dec 20177:00 amRNSTotal Voting Rights
21st Dec 20177:00 amRNSShare cancellation
1st Dec 20177:00 amRNSTotal Voting Rights
7th Nov 20173:07 pmRNSHolding(s) in Company
2nd Nov 20179:18 amRNSConfirmation of share cancellation
1st Nov 20177:00 amRNSTotal Voting Rights
27th Oct 20175:05 pmRNSHolding(s) in Company
3rd Oct 20173:44 pmRNSCancellation of escrow shares PDMR dealing/buyback
21st Sep 201710:16 amRNSHolding(s) in Company
11th Sep 20177:00 amRNSHalf-year Report
6th Sep 20171:41 pmRNSReduction of capital
31st Aug 20177:00 amRNSNotice of Results
10th Aug 20177:00 amRNSHolding(s) in Company
7th Aug 20179:45 amRNSHolding(s) in Company
27th Jul 201711:18 amRNSResult of General Meeting
19th Jul 20178:54 amRNSHolding(s) in Company
6th Jul 20177:00 amRNSTrading update
26th Jun 20177:00 amRNSNotice of GM
26th Jun 20177:00 amRNSCancellation of share options
10th May 201711:45 amRNSResult of AGM
10th May 20177:00 amRNSTrading Update & Structure Update
18th Apr 201712:00 pmRNSAnnual Financial Report
4th Apr 201710:55 amRNSHolding(s) in Company
21st Mar 20171:47 pmRNSDirector/PDMR Shareholding
21st Mar 201712:04 pmRNSHolding(s) in Company
20th Mar 20177:00 amRNSUpdate
20th Mar 20177:00 amRNSFinal Results
2nd Mar 20177:00 amRNSNotice of Results
22nd Feb 20177:00 amRNSChange of Nominated Adviser and Broker
9th Jan 20177:00 amRNSTrading update
7th Nov 20167:00 amRNSTrading update
7th Oct 20167:00 amRNSTrading update
19th Sep 20167:00 amRNSAppointment of Joint Broker
13th Sep 20169:09 amRNSHolding(s) in Company
12th Sep 201610:24 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.